We read with interest the correspondence regarding "Acid-fast bacilli: culture positivity and drug resistance in abdominal tuberculosis". It is well known that breakthrough contamination occurs in TB Mycobacteria Growth Indicator Tube (MGIT) cultures up to 8.1 %; this is even higher for all combined solid media at 21 %. At our CAP-and NABLaccredited mycobacteriology lab, stringent quality control/ assurance practices are in place for every batch of cultures put up to avoid any cross contamination with appropriate negative controls being performed at least four times a day to prevent any breakthrough contamination.
We read with interest the correspondence regarding "Acid-fast bacilli: culture positivity and drug resistance in abdominal tuberculosis". It is well known that breakthrough contamination occurs in TB Mycobacteria Growth Indicator Tube (MGIT) cultures up to 8.1 %; this is even higher for all combined solid media at 21 %. At our CAP-and NABLaccredited mycobacteriology lab, stringent quality control/ assurance practices are in place for every batch of cultures put up to avoid any cross contamination with appropriate negative controls being performed at least four times a day to prevent any breakthrough contamination.
We also appreciate the concerns regarding high rates of resistance. However, we are a tertiary care center with a referral bias towards nonresponders. Prevalence of resistant strains at our institution is hence on the higher side and may not necessarily represent the prevalence in the community. Split-sample analysis of phenotypic drug susceptibility testing (DST) with molecular tests including pyrosequencing is regularly done with good concordance. MGIT DST for SIRE (streptomycin, isoniazid, rifampicin, and ethambutol) currently is a reliable option as in vitro DST results based on the proportion method (which combines the critical concentration of primary antituberculous drugs with a standardized inoculum made from a pure culture of the recovered strain) has been shown to correlate well with clinical response to anti-TB chemotherapy. As regards pyrazinamide, phenotypic susceptibility testing overall agreement of the BACTEC MGIT 960 system with the BACTEC 460TB system for PZA testing was found to be 96.6 % [1] .
